Effective treatment of a refractory hairy cell leukemia variant with splenic pre-irradiation and alemtuzumab.

Effective treatment of a refractory hairy cell leukemia variant with splenic pre-irradiation and alemtuzumab. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Effective treatment of a refractory hairy cell leukemia variant with splenic pre-irradiation and alemtuzumab. Abstract Text:

Makoto Sasaki,Koichi Sugimoto,Takeshi Mori,Kumiko Karasawa,Kazuo Oshimi,

A 72-year-old Japanese man presented with 43.1 x 10(9)/l hairy cells and apparent splenomegaly. The leukemia cells had unevenly distributed microvilli and round nuclei with dense chromatin and one or two clear nucleoli, lacked CD25 expression and were negative for tartrate-resistant acid phosphatase. The case was diagnosed as hairy cell leukemia variant (HCLv) and proved refractory to various chemotherapies, including cladribine, pentostatin, interferon-alpha, CHOP and rituximab. Because of the CD52 expression, we treated the patient with alemtuzumab. Pretreatment with 22.5 Gy to the spleen reduced the spleen size from 12 to 4 cm below the left costal margin, and the number of circulating leukemic cells decreased from 229.0 to 63.6 x 10(9)/l. Subsequent administration of 24.0 mg of alemtuzumab eliminated leukemic cells in the peripheral blood on day 12, and the spleen was not palpable after the administration of 54.0 mg of alemtuzumab. In vitro treatment with alemtuzumab confirmed the cytotoxic effect against the patient's leukemic cells in the presence of complement. This is the first report showing clinical effectiveness of splenic irradiation and alemtuzumab against refractory HCLv.

Effective treatment of a refractory hairy cell leukemia variant with splenic pre-irradiation and alemtuzumab. Publishing Authors By Initials

M Sasaki,K Sugimoto,T Mori,K Karasawa,K Oshimi,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Effective treatment of a refractory hairy cell leukemia variant with splenic pre-irradiation and alemtuzumab. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Acta haematologica

VOLUME: 119

Page Numbers: 48-53

Journal Abbreviation: Acta Haematol.

ISSN: 1421-9662

DAY: 6

MONTH: 02

YEAR: 2008

Effective treatment of a refractory hairy cell leukemia variant with splenic pre-irradiation and alemtuzumab. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 141053

Effective treatment of a refractory hairy cell leukemia variant with splenic pre-irradiation and alemtuzumab. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Effective treatment of a refractory hairy cell leukemia variant with splenic pre-irradiation and alemtuzumab. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Effective treatment of a refractory hairy cell leukemia variant with splenic pre-irradiation and alemtuzumab.

AFFILIATION: Division of Hematology, Department of Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan.

Country: Switzerland

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Acta Haematol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Effective treatment of a refractory hairy cell leukemia variant with splenic pre-irradiation and alemtuzumab Related Publications

• CD20-positive extranodal NK-cell lymphoma, nasal-type.
• Changes in cell morphology and cytoskeletal organization are induced by human mitotic checkpoint gene, Bub1.
• Combination brings long-term remission in acute promyelocytic leukemia refractory for both all-trans retinoic acid and arsenic trioxide.
• Disseminated Mucor infection and thrombotic microangiopathy in lymphoma-associated hemophagocytic syndrome.
• Effective treatment of a refractory hairy cell leukemia variant with splenic pre-irradiation and alemtuzumab.
• Effective written communication for patients with limited English proficiency.
• Hsp90-inhibitor geldanamycin abrogates G(2) arrest in p53-negative leukemia cell lines through the depletion of Chk1.
• Phase I study of dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia.
• Progress in understanding and managing natural killer-cell malignancies.
• Progressive respiratory distress in a patient with splenic marginal zone lymphoma.